BC-004

N/A

Report date: 2026/03/19 17:01:19

Base Information

Drug NameBC-004

Drug Alias NameBC-004

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-HER2Anti-CD3

TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShandong Buchang Pharmaceuticals Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan Luzhou Buchang Biopharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A